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Citrullinemia type 1 was diagnosed by tandem mass spectrometry in a full term male neonate
who presented with an acute catastrophic collapse on the 3rd day of life. Both parents were
identified to be carriers for the exon 15 p Gly390Arg mutation in the argininosuccinate
synthetase gene located at chromosome 9q34.1. Chorionic villus sampling and prenatal
genetic testing in the subsequent pregnancy revealed an affected fetus resulting in
termination of pregnancy.
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Citrullinemia type 1 is a rare potentially lethalurea cycle disorder resulting from deficiencyof argininosuccinate synthetase enzyme. Wereport a case of classic citrullinemia type 1 in a
male full term neonate. A genetic diagnosis was made
using molecular genetic diagnostic tests which facilitated
prenatal genetic diagnosis in the subsequent pregnancy.
CASE REPORT
A fullterm 3.25 kg male neonate was born to a
primigravida mother (non consanguineous marriage,
uncomplicated antenatal period) by emergency caesarean
section for fetal distress. He needed no resuscitation at
birth and was breastfed and remained by mother’s side
until 2 days. Baby was admitted to neonatal intensive care
unit (NICU) at 64 hours of life for retching, lethargy and
poor feeding. On examination he was lethargic and jittery
with stable vital signs, weighed 2.84 kg (12.6% weight
loss) and had a blood glucose of 142 mg/dL. One hour
after admission he developed multifocal clonic fits. Full
septic screen was done. Baby was started on intravenous
fluids and antibiotics.
Hematological and biochemical work-up was non-
contributory. His serum results were normal except
sodium: 158 meq/L, bicarbonate was 13 meq/L, Urea was
20 mg/dL and creatinine was 2 mg/dL. Blood gas,
ammonia and lactate could not be done due to logistic
issues, and a filter paper blood spot test for inborn error of
metabolism (IEM) was done. CSF was normal.
Baby had a progressive worsening of sensorium,
frequent tonic posturing despite phenobarbitone,
worsening tachypnea requiring oxygen, and respiratory
arrest needing mechanical ventilation seven hours after
admission. Baby died at eight hours of admission due to
cardiac arrest. Repeat urea was 21 mg/dL and creatinine
2.3 mg/dL and baby had voided 20 mL urine after
admission.
The tandem mass spectrometry (TMS) of the filter
paper blood spot showed a ten-fold elevation of citrulline
levels to 702 (normal <70) μmol/L thus suggesting the
diagnosis of citrullinemia, a urea cycle disorder. Autopsy
report available two months later revealed normal
viscera, and no inflammatory changes of sepsis.
As EDTA sample of the deceased baby was not
available for genetic study, we recalled the remaining
filter paper blood spot and sent it along with parents’
EDTA samples to Metabolic Lab of Zurich University
Children’s Hospital, Switzerland. Mutation analysis for
the argininosuccinate synthetase (ASS 1) gene was
performed after DNA isolation. Both parents were found
to be carriers of the known mutation in exon 15, p
Gly390Arg of ASS 1 gene at chromosomal location
9q34.1 thus confirming the diagnosis of citrullinemia
type 1.
Prenatal diagnosis was offered in next pregnancy.
This was carried out from the  same laboratory using
DNA of chorionic villous cells and mutational analysis.
The prenatal diagnosis result was consistent with
homozygous mutation of the ASS 1 gene, and termination
of pregnancy was advised.
DISCUSSION
In our case, once hypoglycemia was ruled out as the cause
of lethargy, sepsis was considered although there were no
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antecedents for early onset sepsis. On seeing the results
(normal CSF values, normal CRP) sepsis was unlikely  so
non-infective encephalopathy due to IEM with
hypernatremic dehydration was considered. A cardiac
cause was considered unlikely as the baby was not in
shock or cyanotic and had normal pedal pulses. Increased
serum creatinine was a “red flag” but with normal serum
potassium, acute renal failure was thought unlikely. What
was unexplained initially was the normal urea despite
dehydration, weight loss and elevated creatinine. The
normal urea with a disproportionately raised creatinine is
probably due to defective synthesis of urea. Respiratory
alkalosis due to hyperventilation is the key feature in urea
cycle disorders and the low bicarbonate seen in our
patient could be due to the metabolic compensation for
the low pCO2 in respiratory alkalosis.
Type 1 cirtrullinemia is an autosomal recessive
disorder which often runs a rapidly fulminant course
resulting in neonatal death as in our case.  The underlying
biochemical defect is a defect in the enzyme
argininosuccinate synthetase (ASS) that converts
citrulline to argininosuccinate (3rd step in the urea cycle).
The classical form is very rare with an incidence of 1 in
152500 in the European population [2] but incidences
may be higher in populations with greater consanguinity.
Massive build up of ammonia resulting from this urea
cycle defect causes cerebral edema and encephalopathy
that is rapidly fatal if left untreated [3] consists of using
intravenous sodium benzoate and/or phenylacetate.
Hemodiafiltration is the therapy of choice in severe
hyperammonemic encephalopathy and if it is not
available hemodialysis or hemofiltration should be
rapidly instituted to limit permanent neurological damage
[3]. Notably, levels of plasma citrulline remain strongly
elevated even if long-term pharmaco-therapy and dietary
therapy results in a stable metabolic situation. A large
proportion of patients with initial ammonia concentration
> 300 μmol/L and/or a peak ammonia concentration of
>480 μmol/L have cognitive impairment and residual
neurological damage [4,5]. The longest reported survival
of an untreated infant with classic citrullinemia type 1 is
17 days [4,5].
There have been only four published reports of
citrullinemia in Indian literature before [6,8], Gupta. et
al. [9] have reported genetic diagnosis of three cases of
citrullinemia type 1 with antenatal diagnosis in one. The
present report is only the second in which genetic
diagnosis for citrullinemia is being documented in Indian
literature.
With modern techniques, mutation analysis based on
Sanger sequencing is the method of choice for
confirmation of the diagnosis rendering deletion/
duplication analysis and linkage analysis no longer
necessary in first instance. Sequence analysis by the
methods applied in our case detects about 96% of the
mutations [personal communication, J. Häberle]. Severe
classic citrullinemia type 1 can be caused by very
heterogeneous mutations but the mutation in exon 15
p.Gly390Arg is the most prevalent one associated with
the classic phenotype [10].
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